Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547] ...

In AERIFY-2, however, itepekimab failed to hit this same threshold, showing only a 2% reduction in exacerbations at 52 weeks. “Sentiment has undoubtedly been poor for REGN shares of late following the ...

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.

CDC report confirms no link between thimerosal-containing vaccines and autism or neurodevelopmental disorders. Read more here ...

In April 2025, Sanofi and Regeneron announced that their Phase III AERIFY-1 trial evaluating the fully human monoclonal antibody itepekimab in former smokers with inadequately controlled chronic ...